Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirentelimab in active eosinophilic esophagitis
NCT04322708Phase 3Completed
- Sponsor
- Allakos Inc.
- Start
- Jul 2020
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of lirentelimab in eosinophilic esophagitis (EoE), sponsored by Allakos Inc.. Started Jul 2020; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04322708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04322708.